ALAB Astera Labs Inc

Previous close
$334.17
Est. 12 months change
+42.11%
Projected Price
$476.33

Profitability Metrics

Return on Equity (ROE)
26.13%
Return on Assets (ROA)
17.18%
Return on Invested Capital (ROIC)
72.27%
Weighted Average Cost of Capital (WACC)
26.97%
ROIC - WACC
45.30%
Updated : 2026-08-08 06:25 ET

Valuation Metrics

P/E Ratio
164.88
Forward P/E
84.18
PEG Ratio
1.12
Debt Current Ratio
10.05

Growth & Cash Flow

Gross Margin
75.13%
Operating Margin
22.75%
FCF Margin
23.02%
TTM Revenue Growth
104.45%
Projected 12M EPS Growth
95.85%

Price Change

Price % from 50 SMA
-12.25%
Price % from 200 SMA
-24.32%
6 Months
-44.11%
1 Year
82.80%
2 Years
62.22%
Click here to see the list of ETFs containing ALAB as a top holding :Astera Labs Inc ETFs

Analysis

Company Overview

Astera Labs is a fabless semiconductor company designing connectivity ICs — including PCIe, CXL, and Ethernet retimers — that accelerate data movement inside AI and cloud data centers. Sector: Technology.

Overview

Astera Labs Inc (ALAB) is an individual stock. The analysis below presents key financial metrics for the company, covering profitability, capital efficiency, valuation, margins, and growth.

Profitability & Capital Efficiency

From a capital efficiency perspective, ROIC is 72.27%, WACC is 26.97%, and the economic spread is 45.30%. On balance, the company exhibits an exceptional economic spread, compounding intrinsic value at a rate few companies can match. Supporting metrics show ROE at 26.13% and ROA at 17.18%, a combination that helps frame whether profitability strength is broad enough to hold through different market conditions. Taken together, the return profile suggests a company with credible compounding capacity if current operating execution persists.

Valuation

Multiple analysis puts the company at trailing P/E of 164.88, forward P/E of 84.18, PEG of 1.12. The spread from trailing to forward multiple is wide enough to suggest earnings momentum is a meaningful part of the current valuation case. Growth-adjusted, the company looks reasonably valued — the PEG ratio implies the market is not extrapolating the growth narrative aggressively. The current ratio of 10.05 indicates the company is well-positioned to meet near-term obligations. The combined valuation and liquidity profile points to a company where current prices embed meaningful growth expectations, and where delivery against those expectations will drive the return outcome.

Margins & Cash Generation

On the margin front: gross margin sits at 75.13%, operating margin at 22.75%, and free cash flow margin at 23.02%. At this gross margin level, the company demonstrates significant pricing power and production efficiency. Operating margins sit in a healthy range — not exceptional, but indicating reasonable operational efficiency. Strong free cash flow margins point to businesses with meaningful financial flexibility and limited dependence on external capital. This margin set supports the view that earnings quality is high and cash generation is not merely accounting-driven.

Growth & Forward Outlook

On the forward picture: TTM revenue growth of 104.45% reflecting robust top-line expansion across the company. Consensus EPS estimates point to 95.8% earnings growth over the next 12 months — a compelling near-term earnings catalyst that, if delivered, changes the valuation conversation materially. Analyst price targets suggest street expectations point to meaningful upside if execution holds on a 12-month view. Revenue growth is grounded in reported results; price targets are forward projections that embed assumptions about multiple expansion, earnings delivery, and macro conditions. The key risk in both directions is whether the company can maintain their operating trajectory as macro and sector conditions evolve. The estimated 12-month price change is based on analyst consensus price target estimates, sourced from publicly available data, and should not be interpreted as a reliable prediction of future performance.

Conclusion

Strong Buy

Across the metrics reviewed, the evidence is consistently constructive — quality, growth, and valuation are pulling in the same direction.

The analysis above draws from quantitative data only and does not constitute personalized financial advice. Investors should conduct independent research and consider professional guidance before acting on any information presented here.